Second-line pembrolizumab after progression on sorafenib benefits OS/PFS in advanced HCC Presented ByProf. Philippe Merle, University Hospital Lyon, France TrialPhase 3, KEYNOTE-240 ConferenceASCO GI 2021 12 March, 2021 11:37
